Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vipidia

- PMLiVE

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

Final European approval around the corner - but reimbursement and specialist centres among outstanding issues

- PMLiVE

Daily Brief: Europe changes mind on Puma drug, Pfizer’s Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest

The latest from pharma, biotech and healthcare

- PMLiVE

Boehringer beefs up biologics capacity with €230m investment

New facility to focus on analytical and process development and manufacturing of biologics for trials.

- PMLiVE

Daily Brief: Andrew Witty’s replacement on Accelerated Access initiative, Blincyto gains full EU approval and more

The latest news from across pharma, biotech and healthcare

- PMLiVE

New trial results suggest CAR-T effects are durable in lymphoma

Novartis and Celgene/Juno release longer term data on important lymphoma indication at EHA

- PMLiVE

Daily Brief: Keytruda and microbiome synergy, Pfizer’s files PARP contender and more

Your daily injection of pharma news

- PMLiVE

Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report

Orphan drug sales growth will be 11%+ a year

- PMLiVE

Novartis bribery probe in Greece ‘could affect general election’

The pharma giant allegedly gave “bundles of cash” to civil servants, doctors and politicians

- PMLiVE

Daily Brief: ASCO latest, Europe cautions on immunotherapy, rejects Duchenne treatment

All the latest from the frontline of pharma, biotech and healthcare

- PMLiVE

ICER says price of Amgen/Novartis’ Aimovig is OK – if used last-line

Recommends the drug should only be used in patients who have exhausted other prevention options

EphMRA Annual Conference 2018

Visit us on stand number 20

Research Partnership

Novartis changes executive committee

Robert Welteverden is appointed head of Novartis Business Services

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links